Attached files
file | filename |
---|---|
8-K - FORM 8-K - OSTEOTECH INC | c60730e8vk.htm |
Exhibit 99.1
Contacts | ||||
Company: | Mark H. Burroughs | |||
FOR IMMEDIATE RELEASE
|
(732) 542-2800 | |||
Investors: | Jennifer Beugelmans | |||
(646) 596-7473 | ||||
Media: | Dan Budwick | |||
(973) 271-6085 | ||||
October 13, 2010 |
Osteotech Announces Early Termination of HSR Waiting Period
Osteotech, Inc. (NASDAQ: OSTE), a leader in the emerging field of biologic products for
regenerative healing, announced today that it has received notification that the U.S. Department of
Justice and Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting
period for its proposed merger with Medtronic, Inc. The closing of the merger remains subject to
antitrust clearance in foreign jurisdictions and approval by Osteotech stockholders at the special
meeting to be held on November 9, 2010, as well as other customary closing conditions.
About Osteotech
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic
solutions for regenerative medicine to support surgeons and their patients in the repair of the
musculoskeletal system through the development of innovative therapy-driven products that alleviate
pain, promote biologic healing and restore function. For further information regarding Osteotech,
please go to Osteotechs website at www.osteotech.com.
Additional Information about the Proposed Transaction and Where You Can Find It
Osteotech has filed with the Securities and Exchange Commission (the SEC) a definitive proxy
statement in connection with the proposed acquisition of Osteotech by Medtronic. The definitive
proxy statement is being mailed to Osteotech stockholders on October 14, 2010. Before making any
voting or investment decisions with respect to the transaction, investors and stockholders of
Osteotech are urged to read the proxy statement when it becomes available because it contains
important information about the transaction, Osteotech and Medtronic. Investors and stockholders
may obtain free copies of the definitive proxy statement and other documents filed with the SEC at
the SECs web site at www.sec.gov. In addition, investors and stockholders may obtain free copies
of the documents filed with the SEC by accessing Osteotechs website at www.osteotech.com or by
writing Osteotech to the attention of the Assistant Secretary at 51 James Way, Eatontown, New
Jersey, 07724.
Information Regarding Participants
Osteotech, Medtronic and their respective directors, executive officers and certain other members
of management and employees may be soliciting proxies from Osteotech stockholders in favor of the
merger. Information regarding the persons who may, under the rules of the SEC, be considered
participants in the solicitation of the Osteotech stockholders in connection with the proposed
merger will be set forth in the proxy statement when it is filed with the SEC. You can find
information about Medtronics executive officers and directors in its definitive proxy statement
filed with the SEC on July 16, 2010. You can obtain a free copy of this document at the SECs web
site at www.sec.gov, or by accessing Medtronicss website at www.Medtronic.com and clicking on the
Investors link. You can find information about Osteotechs executive officers and directors in its
definitive proxy statement filed with the SEC August 3, 2010. You can obtain a free copy of this
document at the SECs web site at www.sec.gov or by accessing Osteotechs website at
www.osteotech.com or by writing Osteotech to the attention of the Assistant Secretary at 51 James
Way, Eatontown, New Jersey, 07724.
# # #